As part of the expansion, the companies have renewed collaboration in Brazil and Argentina and also extended the partnership to Australia where Galderma will have exclusive promotion and distribution rights for Dysport in glabellar lines indication.
The companies have also agreed to co-promote Dysport and Restylane in South Korea.
Ipsen chairman and CEO Marc de Garidel said, "The extension of our collaboration to new territories demonstrates the quality of our fruitful relationship to achieve this successful partnership for patient care."
Galderma president and chief executive officer Humberto Antunes said, ”We are convinced that, along with Restylane®, Dysport® has become one of the leaders in the Aesthetic muscle relaxant market.”
The renewed agreements in Brazil and Argentina, which will come into force in January 2013, will carry on for an additional five-year period.
In 2009, Ipsen granted Galderma exclusive rights to develop, promote and distribute its botulinum toxin type A product in the European Union and certain territories of the Middle-East and Eastern Europe.
Dysport is a neuromuscular blocking toxin, which blocks acetylcholine release at motor nerve ends and reduces muscular spasm.